BEACOPP: A new regimen for advanced Hodgkin's disease

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Diehl, V ^a   Franklin, J ^a   Hasenclever, D ^a   Tesch, H ^a   Pfreundschuh, M ^a   Lathan, B ^a   Paulus, U ^a   Sieber, M ^a   Ruffer J U ^a   Sextro, M ^a   Engert, A ^a   Wolf, J ^a   Hermann, R ^a   Holmer, L ^a   Stappert Jahn, U ^a   Winnerlein Trump, E ^a   Wulf, G ^a   Krause, S ^a   Glunz, A ^a   Von Kalle, K ^a   Bischoff, H ^a   Haedicke, C ^a   Duhmke E ^a   Georgii, A ^a   Loeffler, M ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotheapy; Dose escalation; Efficacy; Hodgkin's disease; Toxicity

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECOND CANCER; THROMBOCYTOPENIA;

EID: 0032456756     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S67     Document Type: Conference Paper

References (12)

1. De Vita VT, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term followup of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-95.
2. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 1975; 36: 252-9.
3. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
4. Cullen MH, Stuart NSA, Woodruffe C et al. ChlVPP/PABIOE and radiotherapy in advanced Hodgkin's disease. J Clin Oncol 1994; 12: 779-87.
5. Sieber M, Rueffer U, Tesch H et al. Rapidly alternating COPP + ABV + IMEP (CAI) is equally effective as alternating COPP + ABVD (CA) for Hodgkin's disease: Final results of two randomised trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. American Society of Hematology 39th Annual Meeting. Blood 1997; 90 (Abstr 2605).
6. Hancock BW, Vaughan-Hudson G, Vaughan-Hudson B et al. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: A prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol 1994; 5 (Suppl 2): 117-20.
7. Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15: 1638-45.
8. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-30.
9. De Vita VT Jr, Hubbard SM, Longo DL. The chemotherapy of Hodgkin's disease: Looking back, moving forward - the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987; 47: 5810-24.
10. Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. Ann Oncol 1998; 9 (Suppl 5): S73-8 (this issue).
11. Diehl V, Loeffler M, Pfreundschuh M et al. for the German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 1995; 6: 901-10.
12. Diehl V, Sieber M, Ruffer U et al. for the German Hodgkin's Lymphoma Study Group. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997; 8: 1-6.